Qizhi Diao | Medicine and Dentistry | Research Excellence Award

Posted on by Phenomenological Research

Research Excellence Award

Qizhi Diao
Hainan Branch, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, China
Qizhi Diao
Affiliation Shanghai Jiao Tong University
Country China
Designation Professor
Scopus ID 52563308500
Documents 19
Citations 252
h-index 9
Subject Area Medicine and Dentistry
Event International Phenomenological Research Awards
ORCID 0000-0003-1121-4656

Qizhi Diao is a professor affiliated with the Hainan Branch of Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Sanya, China. His academic work has focused on the synthesis of functional nanomaterials, the construction of advanced clinical diagnostic sensors, and the development of nanocarrier-mediated therapeutic systems for biomedical applications. His research activities have contributed to innovations in biosensing technologies, point-of-care diagnostics, CRISPR/Cas-enabled sensing systems, and nanopharmaceutical delivery platforms.[1] Diao has participated in multiple nationally and provincially funded scientific projects related to cancer diagnostics, SARS-CoV-2 detection technologies, and exosome identification systems within nucleic acid assembly frameworks.[2]

Abstract

The academic contributions of Qizhi Diao are associated with interdisciplinary developments in nanomedicine, biosensor engineering, and clinical laboratory technologies. His research has emphasized the design of graphdiyne-based nanostructures, electrochemical sensing systems, nanozyme-assisted diagnostics, and portable point-of-care biosensing platforms. Through projects supported by the National Natural Science Foundation of China and regional scientific agencies, Diao has contributed to the development of technologies for detecting infectious diseases, circulating tumor cells, and gastric cancer biomarkers.[3] His work integrates materials science, clinical diagnostics, and biomedical engineering into translational research frameworks applicable to modern laboratory medicine.

Keywords

Nanomaterials; Graphdiyne; Clinical Diagnostic Sensors; CRISPR/Cas Technology; Electrochemical Biosensors; Nanopharmaceuticals; Targeted Drug Delivery; Nanozymes; Medical Laboratory Technology; Point-of-Care Diagnostics; Biomedical Engineering; Electrochemical Sensing.

Introduction

Recent advancements in biomedical engineering and nanotechnology have accelerated the development of highly sensitive diagnostic platforms and targeted therapeutic systems. Within this scientific context, Qizhi Diao has conducted research aimed at integrating nanomaterial synthesis with clinical laboratory applications. His work has addressed major challenges in biosensing accuracy, rapid pathogen detection, and nanocarrier-mediated therapeutic delivery systems.[4]

Qizhi Diao’s investigations into graphdiyne-based sensing systems and nanozyme catalytic materials have contributed to the broader understanding of electrochemical diagnostics and biosensor miniaturization. His projects have also focused on CRISPR/Cas-mediated detection systems capable of improving diagnostic sensitivity for infectious diseases and cancer-associated biomarkers.[5]

Research Profile

Qizhi Diao has maintained a long-term academic focus on the fabrication of functional nanomaterials, clinical diagnostic sensors, and nanocarrier-mediated drug delivery systems. His institutional affiliations include the Hainan Branch of Shanghai Children’s Medical Center and Shanghai Jiao Tong University School of Medicine.[1]

His completed and ongoing projects include:

  • Research on encoding for the identification of plasma exosome subtypes based on confined recognition and amplification systems within nucleic acid assembly frameworks funded by the National Natural Science Foundation of China.
  • Portable sensors for simultaneous detection of multiple gastric cancer biomarkers using CRISPR/Cas technology funded by the Hainan Provincial Health Commission.
  • Point-of-care quantitative detection systems for SARS-CoV-2 nucleic acids using graphdiyne sub-nanosheets supported by the Natural Science Foundation Project of Chongqing.
  • Novel 3D magnetic nanocomposites based on graphdiyne-MOFs for simultaneous capture and chemotherapy of circulating tumor cells in peripheral blood.
  • Development of graphdiyne-based systems for the detection of SARS-CoV-2 antigen biomarkers under emergency biomedical research initiatives.

His scientific profile additionally includes responsibilities as an ISO 15189 medical laboratory accreditation assessor and research review expert for multiple scientific organizations and governmental institutions in China.[6]

Research Contributions

Among Qizhi Diao’s reported scientific contributions is the synthesis of sub-nanoscale graphdiyne materials for the rapid and quantitative detection of Mycobacterium tuberculosis and drug-resistant genes.[7] This work supported the development of fluorescence sensing systems with improved analytical sensitivity and operational simplicity.

He also contributed to the preparation of core-shell nanozymes such as ZrFe-MOF@PtSn exhibiting strong peroxidase-like catalytic properties for biosensing applications. Additionally, his research integrated miRNA-initiated strand displacement amplification with CRISPR/Cas12a amplification strategies, nanozyme catalysis, and machine-learning-assisted electrochemical sensing systems.[8]

Qizhi Diao has further contributed to patents related to electrochemical immunosensors, medical testing oscillation devices, and laboratory inspection equipment. These developments reflect the translational dimension of his work in clinical laboratory technologies.[9]

Publications

Qizhi Diao has published research in internationally recognized journals focusing on nanotechnology, biomedical sensing, and clinical diagnostic systems. His publications explore graphdiyne-based fluorescent sensing platforms for detecting Mycobacterium tuberculosis and drug-resistant genes, nanoparticle-based drug delivery systems for cardiovascular diseases, and nanozyme-assisted biosensing technologies for rapid pathogen detection. He has also contributed to studies on high-porosity carbon electrocatalysts and amino-functionalized carbon nanodots for biomedical applications. His scholarly work integrates nanomaterials, electrochemical sensing, CRISPR/Cas technologies, and translational laboratory medicine, supporting advancements in point-of-care diagnostics, targeted therapeutics, and innovative clinical biosensor development.

Research Impact

The research activities of Qizhi Diao have contributed to interdisciplinary developments linking nanotechnology, laboratory medicine, and biomedical sensing systems. His work on graphdiyne nanostructures and nanozyme catalytic platforms has been associated with improved biosensor sensitivity and enhanced diagnostic performance in infectious disease detection.[10]

According to the provided academic indicators, his research record includes an h-index of 9 and more than 252 citations indexed through Scopus, in addition to reported Web of Science citations exceeding 300.[11] His collaborative work with organizations such as the Chinese Medical Doctor Association and the Chinese Medical Association has also supported laboratory medicine standardization and diagnostic research initiatives.

Award Suitability

The academic profile of Qizhi Diao demonstrates sustained engagement in translational biomedical research, particularly within nanomaterials, biosensors, and clinical diagnostics. His involvement in nationally funded scientific projects, patented technologies, and peer-reviewed publications indicates an active contribution to applied medical research and laboratory innovation.

His combination of scientific output, technical expertise, research leadership, and participation in accreditation and evaluation activities supports consideration for the Research Excellence Award under the International Phenomenological Research Awards framework.

Conclusion

Qizhi Diao has contributed to the advancement of nanotechnology-enabled diagnostic systems and biomedical sensing platforms through interdisciplinary scientific research. His work combines materials engineering, electrochemical sensing, nanozyme catalysis, and clinical laboratory applications into translational biomedical solutions. Through publications, funded research projects, patents, and scientific service roles, he has established a research profile connected to contemporary developments in medical diagnostics and nanomedicine.

References

  1. International Phenomenological Research Awards. (2026). Award nomination application form: Qizhi Diao. https://phenomenologicalresearch.com/
  2. National Natural Science Foundation of China. Research project information related to biomedical sensing and exosome identification systems.
  3. Diao Q. Research projects and biomedical sensing technologies associated with clinical diagnostics and nanomaterials research.
  4. Shanghai Jiao Tong University School of Medicine. Biomedical nanotechnology and laboratory medicine research activities.
  5. CRISPR/Cas biosensing applications in rapid diagnostic systems and molecular detection technologies.
  6. China National Accreditation Service for Conformity Assessment (CNAS). ISO 15189 medical laboratory accreditation activities and technical assessment programs.
  7. Chang F, Huang L, Guo C, Xie G, Li J, Diao Q. (2019). Graphdiyne-Based One-Step DNA Fluorescent Sensing Platform for the Detection of Mycobacterium tuberculosis and Its Drug-Resistant Genes. ACS Applied Materials & Interfaces. https://pubs.acs.org/doi/abs/10.1021/acsami.9b15248
  8. Yang F, Xue J, Wang G, Diao Q. (2022). Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2022.999404
  9. Chinese patent documentation related to electrochemical immunosensors, laboratory inspection devices, and medical testing technologies.
  10. Feng T, Liao W, Li Z, Sun L, Shi D, Guo C, Huang Y, Wang Y, Cheng J, Li Y, Diao Q. (2017). Heavily Graphitic-Nitrogen Self-doped High-porosity Carbon for the Electrocatalysis of Oxygen Reduction Reaction. Nanoscale Research Letters. https://link.springer.com/article/10.1186/s11671-017-2364-6
  11. Elsevier. (n.d.). Scopus author details: Qizhi Diao, Author ID 52563308500. Scopus. https://www.scopus.com/authid/detail.uri?authorId=52563308500

Franziska Münz | Medicine and Dentistry | Future Science Leader Award

Posted on by Phenomenological Research

Dr. Franziska Münz | Medicine and Dentistry | Future Science Leader Award 

Physician at Universität Heidelberg | Germany

Dr. Franziska Münz is a promising researcher in the field of Medicine and Dentistry, demonstrating strong scientific impact through 10 scholarly documents that have collectively received 97 citations across 88 academic works, alongside an h-index of 5. Her research contributions focus on advancing medical knowledge through evidence-based approaches, particularly in clinically relevant and translational domains. Her work reflects a commitment to improving healthcare outcomes by exploring innovative methodologies and interdisciplinary perspectives. With a growing citation record and consistent publication output, Dr. Franziska Münz shows clear potential as an emerging leader in future scientific advancements. Her research trajectory highlights both quality and influence, positioning her as a valuable contributor to the global medical research community and a strong candidate for recognition under the Future Science Leader Award.

Citation Metrics

100

75

50

25

0

Citations
97

Documents
10

h-index
5

View Scopus Profile

Top 5 Publications

Rolf Teschke | Medicine and Dentistry | Best Paper Award

Posted on by Phenomenological Research

Prof. Rolf Teschke | Medicine and Dentistry | Best Paper Award

Professor at Klinikum Hanau | Germany

Prof. Rolf Teschke is an internationally recognized expert in hepatology whose distinguished career has significantly influenced contemporary understanding of liver diseases, hepatotoxicity, and drug-induced liver injury. Educated at leading medical institutions and trained in internal medicine with specialization in gastroenterology and hepatology, he advanced early in his career through rigorous scientific and clinical environments that shaped his enduring interest in hepatic metabolism and toxicology. His research journey includes extensive work in experimental hepatology, where he contributed pivotal insights into microsomal ethanol-oxidizing systems, cytochrome P450 related pathways, and the biochemical mechanisms underlying alcohol-associated and toxin-induced liver damage. Over several decades, Prof. Rolf Teschke has held prominent academic and clinical positions, leading major medical departments and contributing to both patient care and research innovation. His expertise is particularly well known for advancing causality assessment methodologies in drug-induced liver injury, especially through his influential work with the RUCAM system, which has become a globally referenced tool in hepatotoxicity evaluation. Throughout his career, he has produced a substantial body of peer-reviewed literature, reflecting profound scientific productivity and impact. His publication record includes 171 documents, supported by 6,888 citations across 4,040 citing documents, and an impressive h-index of 48, underscoring the depth, relevance, and international recognition of his work. Prof. Rolf Teschke’s research interests span alcoholic liver disease, herbal and drug hepatotoxicity, biochemical enzymology, and clinical hepatology, integrating laboratory discoveries with real-world clinical applications to improve diagnostic standards and therapeutic strategies. He has authored and co-authored more than 250 publications, including articles, book chapters, and comprehensive reviews, contributing to foundational knowledge used by clinicians, toxicologists, and regulatory bodies worldwide. In addition to research, he has served in editorial roles for several journals, helping guide scientific discourse in hepatology and liver toxicology. Overall, Prof. Rolf Teschke’s career reflects a sustained commitment to advancing scientific excellence, improving patient outcomes, and shaping global best practices in the study of liver injury, marking him as one of the leading contributors to modern hepatology.

Profile; Scopus | Orcid

Featured Publications:

Teschke, R. Drug-Induced Autoimmune Hepatitis by Varenicline and Infliximab as a Continuous Disease Spectrum with Two Different Flares: Acute Liver Injury Followed by Hepatic Autoimmunity. Review.
Annotation: Discusses two-step autoimmune hepatitis triggered by pharmaceutical agents, highlighting diagnostic and clinical implications.

Teschke, R. Acute Liver Failure with Determinate rather than Indeterminate Etiology Facilitates Therapy and May Avoid Liver Transplantation: A Critical Analysis. Review.
Annotation: Evaluates clinical outcomes in acute liver failure and argues the benefits of precise etiological identification.

Teschke, R., et al. Drug-Induced Autoimmune Hepatitis: Robust Causality Assessment Using Two Different Validated and Scoring Diagnostic Algorithms. Review.
Annotation: Compares two validated diagnostic algorithms to strengthen causality assessment in drug-induced autoimmune hepatitis.

Teschke, R. Immunology Highlights of Four Major Idiosyncratic DILI Subtypes Verified by the RUCAM: A New Evidence-Based Classification. Review.
Annotation: Proposes an evidence-based immunological classification for idiosyncratic drug-induced liver injury (DILI).

Teschke, R., et al. Metabolic Mysteries of Copper Dysregulation in Wilson Disease. Review.
Annotation: Explores metabolic pathways and unresolved mechanisms underlying copper dysregulation in Wilson’s disease.

Teschke, R., et al. Open Questions on How Metabolic Dysfunction-Associated Steatotic Liver Disease Shapes the Course of Drug-Induced Liver Injury. Letter.
Annotation: Raises key unresolved scientific and clinical questions on the interaction between MASLD and DILI.

Teschke, R. Liver Injury in Immune Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Five New Classification Types. Review.
Annotation: Introduces a new five-type classification system for liver injury associated with severe immune-mediated skin reactions.

Teschke, R. Acute Liver Failure Due to Assumed Drug Induced Liver Injury but Lack of Any Validated Causality Algorithm: Evidence by 36 Cohort Reports with 21,709 Cases. Review.
Annotation: Critically analyzes large cohorts revealing gaps in validated causality assessment for assumed DILI-related acute liver failure.

Teschke, R. Idiosyncratic Hepatocellular Drug-Induced Liver Injury by Flucloxacillin with Evidence Based on RUCAM and HLA B57:01 Genotype.* Review.
Annotation: Examines metabolic and immune mechanisms underlying flucloxacillin-induced hepatocellular injury.

Teschke, R., et al. Successful Corticosteroid Therapy for Severe Liver Injury Secondary to Herbal Traditional Chinese Medicine Mega Defends X: A Case Report. Article, 2024.
Annotation: Documents a clinically significant case showing steroid responsiveness in herb-induced liver injury assessed by updated RUCAM.

Sun Jong Kim | In Vitro Diagnostics | Science and Technology Pioneer Award

Posted on by Phenomenological Research

Dr. Sun Jong Kim | In Vitro Diagnostics | Science and Technology Pioneer Award 

Researcher at BioFront | South Korea

Dr. Sun Jong Kim is a highly accomplished biotechnology and life sciences professional whose career reflects sustained contributions to in vitro diagnostics, stem cell science, biomolecular research, and translational biomedical innovation. Equipped with a strong academic foundation including bachelor’s, master’s, and doctoral studies in life sciences, Dr. Sun Jong Kim has developed deep expertise in cellular biology, developmental biology, and molecular mechanisms of pluripotency. His professional journey includes senior research and leadership roles across multiple biomedical organizations, where he has guided R&D programs involving the establishment and maintenance of pluripotent stem cell lines, large-scale microalgae production systems, medical device development, and regulatory preparation for diagnostic technologies. He has contributed to the development of human embryonic stem cell resources, in vitro differentiation platforms, and advanced diagnostic systems applied to areas such as oncology, COVID-19 rapid testing, and point-of-care technologies. His industrial leadership also includes oversight of product development pipelines, quality assurance systems, and multidisciplinary research operations, demonstrating an ability to translate scientific results into usable biomedical solutions that directly support clinical and research infrastructures. His research outputs include numerous scientific publications, national and international presentations, and patents in areas such as stem cell culturing techniques, photobioreactors, and biomaterial-based innovations. The measurable impact of his scholarly contribution is represented by 24 citations by 24 documents, 2 indexed documents, and an h-index of 2, reflecting ongoing engagement and recognition within the scientific community. Dr. Sun Jong Kim’s research interests encompass stem cell biology, human cell culture systems, the regulation of self-renewal and differentiation pathways, bioprocess design, clinical diagnostics, and biotechnology commercialization. His work has been supported by significant research grants and has contributed to advancements in both academic discovery and applied biomedical engineering. In addition to laboratory research, he has played a crucial role in the development, certification, and evaluation of diagnostic medical devices aligned with international regulatory standards and real-world clinical needs. Through his ongoing work at Biofront and other institutions, Dr. Sun Jong Kim continues to drive innovation in science and technology, contributing to advancements that support more accurate diagnostics, greater understanding of biological systems, and the modernization of biomedical tools used in healthcare and life science research.

Profile: Scopus

Featured Publications:

Kim, S. J.,(1999). Isolation of developmentally regulated novel genes based on sequence identity and gene expression patterns. Molecules and Cells, 9, 207–218.

Kim, S. J.,(2001). Ovarian expression of melatonin Mel(1) receptor mRNA during mouse development. Molecular Reproduction and Development, 59, 126–132.

Kim, S. J.,(2003). Isolation and culture of human embryonic stem-like cells from abnormal blastocysts. Korean Journal of Fertility and Sterility, 30, 293–301.

Kim, S. J.,(2003). Establishment and maintenance of human embryonic stem cells on STO, a permanently growing cell line. Biology of Reproduction, 69, 2007–2014.

Kim, S. J.,(2004). Establishment of embryonic germ cells from cultured human primordial germ cells and their differentiation into neuronal cells. Molecules and Cells, 17, 309–315.

Kim, S. J.,(2004). Recent advances in human embryonic stem cell research. Journal of the Korean Medical Association, 918–925.

Kim, S. J.,(2004). Effects of type IV collagen and laminin on the cryopreservation of human embryonic stem cells. Stem Cells, 22, 950–961.

Kim, S. J.,(2004). Available human feeder cells for the maintenance of human embryonic stem cells. Reproduction, 128, 727–735.

Iker Alonso González | Medicine and Dentistry | Best Researcher Award

Posted on by Phenomenological Research

Mr. Iker Alonso González | Medicine and Dentistry | Best Researcher Award 

FACULTATIVO ESPECIALISTA MEDICO-TECNICO EN MICROBIOLOGÍA Y PARASITOLOGÍA at Cruces University Hospital | Spain

Mr. Iker Alonso González is a dedicated researcher and professional in the field of microbiology and clinical parasitology, recognized for his growing contributions to medical and pharmaceutical sciences. He holds a degree in Pharmacy from the University of the Basque Country (UPV/EHU) and has further specialized in Microbiology and Clinical Parasitology at Cruces University Hospital, where he continues to advance his expertise in infectious disease research and diagnostics. His professional experience at Osakidetza the Basque Health Service combines clinical practice with applied research, focusing on microbial resistance, infectious disease control, and antibiotic stewardship. He has presented numerous research communications, including fourteen posters and two oral presentations at the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), addressing critical topics such as antimicrobial resistance patterns in Shigella spp. and the clinical impact of post-treatment uroculture interventions. His scientific publication, “Multiresistant Aeromonas hydrophila bacteremia,” published in Enferm Infecc Microbiol Clin (Engl Ed), reflects his analytical approach and contribution to understanding emerging multidrug-resistant pathogens. His current research interests center around the development of evidence-based antimicrobial protocols, optimization of laboratory diagnostics, and epidemiological monitoring of infectious diseases in clinical settings. Mr. Iker Alonso González’s participation in national research forums and professional societies highlights his commitment to academic collaboration and scientific advancement. His early scholarly impact is reflected in his record of 2 citations by 2 documents, 3 published works, and an h-index of 1, indicating a promising trajectory in medical research. He is also engaged in continuous professional development, ensuring alignment with global standards in clinical microbiology and pharmaceutical practice. Through his rigorous research, clinical application, and scholarly engagement, Mr. Iker Alonso González exemplifies the integration of scientific inquiry and healthcare innovation, contributing to the ongoing efforts to enhance antimicrobial stewardship and patient outcomes in contemporary medicine.

Profile: Scopus

Featured Publications:

  • Alonso-González, I. (2025). Upper limb abscess due to an unusual Clostridium species in an immunocompetent child. Enfermedades Infecciosas y Microbiología Clínica.

  • Alonso-González, I. (2023). Sensitivity profile of Shigella spp. isolates in patients with travelers’ diarrhea in a tertiary hospital in the period 2017–2022. Presented at the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).

  • Alonso-González, I. (2023). Impact of a PROA intervention on the request of non-proven post-treatment control urocultures. Presented at the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).

  • Alonso-González, I. (2022). Multiresistant Aeromonas hydrophila bacteremia. Enfermedades Infecciosas y Microbiología Clínica

 

Ying Ren | Biomedical Engineering | Best Researcher Award

Posted on by Phenomenological Research

Mrs. Ying Ren | Biomedical Engineering | Best Researcher Award

Lecturer at Xuzhou Medical University, China.

Ying Ren, a dedicated researcher in biomedical engineering, specializes in odontogenic and osteogenic differentiation of bone marrow stem cells. Her work focuses on natural bioactive hydrogels to enhance bone tissue regeneration. She holds a Ph.D. from Peking Union Medical College, Tsinghua University Health Science Center and a Bachelor’s degree from Tianjin Medical University. Currently, she serves as a Lecturer at Xuzhou Medical University. Ying has published extensively in high-impact journals like ACS Applied Bio Materials and Biomaterials, making significant contributions to stem cell-based regenerative medicine.

Professional Profile:

Scopus

Suitability for Best Researcher Award – Dr. Ying Ren

Dr. Ying Ren is an outstanding candidate for the Best Researcher Award, given her pioneering contributions to biomedical engineering, particularly in stem cell-based regenerative medicine. Her expertise in hydrogel engineering for bone and cartilage regeneration has led to groundbreaking advancements in tissue repair. With a Ph.D. from Peking Union Medical College and extensive research in bioactive materials, she has made significant strides in translational medicine, bridging laboratory research with clinical applications.

Education & Experience 🎓💼

✅ Ph.D. in Biomedical Engineering (2015-2021) – Peking Union Medical College, Tsinghua University Health Science Center
✅ Bachelor’s in Pharmacy (2011-2015) – Tianjin Medical University
✅ Lecturer (2021-Present) – School of Stomatology, Xuzhou Medical University

Professional Development 🚀📚

Ying Ren has made groundbreaking advancements in biomaterials, particularly hydrogel-based scaffolds for stem cell differentiation and cartilage repair. Her expertise spans 3D cell culture, regenerative medicine, and bioactive material synthesis. She actively collaborates on interdisciplinary research integrating biomedical engineering, nanotechnology, and tissue regeneration. As a university lecturer, she mentors students in stem cell biology and biomaterials science, fostering the next generation of researchers. Her work contributes to novel therapies for bone and cartilage repair, bridging the gap between fundamental research and clinical applications.

Research Focus 🔬🧪

Ying Ren specializes in stem cell-based regenerative medicine, focusing on:
🦴 Bone & Cartilage Regeneration – Developing bioactive hydrogels for osteogenic and odontogenic applications.
🧫 Hydrogel Engineering – Designing hyaluronic acid-based and gelatin-hyaluronic acid double cross-linked hydrogels for improved stem cell differentiation.
🧪 Biomedical Nanotechnology – Exploring modified citrus pectin and microcapsule technologies for enhanced cell therapy and tissue repair.
🦠 Stem Cell Differentiation Mechanisms – Investigating molecular pathways that maintain stemness and promote mesenchymal stem cell differentiation.

Awards & Honors 🏅🎖️

🏆 Multiple Publications in Prestigious Journals – ACS Applied Bio Materials, Biomaterials, Colloids and Surfaces B: Biointerfaces
🏆 Recognized for Contributions in Biomedical Engineering & Stem Cell Research
🏆 Academic Excellence & Leadership at Xuzhou Medical University
🏆 Key Contributor to Innovative Research in Bioactive Hydrogels

Publication Top Notes

📄 The effects of stiffness on the specificity and avidity of antibody-coated microcapsules with target cells are strongly shape dependent – Colloids and Surfaces B: Biointerfaces 📅 2024 🔍 Cited by: 1